Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $363.71M | $305.21M | $245.36M | $188.46M | $164.41M | $136.47M | $9.84M | N/A |
| Cost of Revenue | $85.74M | $65.57M | $55.13M | $44.15M | $39.87M | $24.21M | $2.42M | $2.90M |
| Gross Profit | $277.96M | $239.63M | $190.23M | $144.31M | $124.54M | $112.25M | $7.41M | $-2.90M |
| Gross Margin | 76.43% | 78.52% | 77.53% | 76.57% | 75.75% | 82.26% | 75.36% | 0.00% |
| Operating Expenses | $1.16B | $949.26M | $647.55M | $519.40M | $389.77M | $347.50M | $314.75M | $186.02M |
| Operating Income | $-878.25M | $-709.63M | $-457.32M | $-375.09M | $-265.23M | $-235.25M | $-307.34M | $-188.92M |
| Operating Margin | -241.47% | -232.51% | -186.39% | -199.03% | -161.32% | -172.38% | -3124.94% | 0.00% |
| Net Income | $-913.77M | $-749.57M | $-481.53M | $-434.65M | $-294.09M | $-254.34M | $-324.28M | $-192.65M |
| Net Margin | -251.24% | -245.59% | -196.26% | -230.63% | -178.87% | -186.37% | -3297.17% | 0.00% |
| EPS (Basic) | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 | $-4.22 | $-2.89 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |